ACER stock forecast
Our latest prediction for Acer Therapeutics, Inc.'s stock price was made on the Aug. 1, 2018 when the stock price was at 21.29$.
In the short term (2weeks), ACER's stock price should outperform the market by 4.11%. During that period the price should oscillate between -9.58% and +14.43%.
In the medium term (3months), ACER's stock price should outperform the market by 4.28%. During that period the price should oscillate between -20.88% and +33.04%.Get email alerts
About Acer Therapeutics, Inc.
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.74$ per share.
The book value per share is 1.40$
Three months stock forecastAug. 1, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|